Over 3 million total prevalent cases of axial spondyloarthritis estimated across the analyzed markets in 2015, with modest growth forecasted.
By Amy Brenner, Epidemiologist
27 May 2016
I joined Datamonitor Healthcare as an Epidemiologist in 2015 after completing an MSc in Epidemiology from the London Sch...
Read full bio
Datamonitor Healthcare estimates that there were over 3 million total prevalent cases of axial spondyloarthritis (AxSpA) across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) in 2015. This comprised around 2 million total prevalent cases of ankylosing spondylitis (AS) and over 1 million cases of non-radiographic axial spondyloarthritis (nr-AxSpA). Of all prevalent cases of AxSpA in 2015, almost 2 million were diagnosed. Japan accounted for less than 1% of the total prevalent cases of AxSpA in 2015. This reflects the low prevalence of the human-leukocyte antigen (HLA)-B27 mutation in Asian populations, which is currently the major known risk factor for AxSpA.
Across the analyzed markets, the number of total prevalent AxSpA cases is predicted to increase by approximately 9% between 2015 and 2035. This trend is driven by population dynamics, including population growth and aging, which are expected to affect the prevalent populations of AS and nr-AxSpA differently. Between-country differences in population demographics are responsible for geographic variation in forecasted trends, with some countries expected to see a decline.
Trend in total prevalent cases of axial spondyloarthritis in the US, Japan, and five major EU markets, by country, 2015–35
Datamonitor Healthcare’s Epidemiology: Axial Spondyloarthritis module provides a detailed epidemiological analysis of the total and diagnosed prevalence of AxSpA, AS, and nr-AxSpA across the US, Japan, and five major EU markets. This includes 20-year total and diagnosed prevalence forecasts for each indication (2015–35), age and gender segmentations for AS, and an analysis of clinical features of AS and nr-AxSpA, as well as an interactive epidemiology datapack that incorporates treatment data from Datamonitor Healthcare’s proprietary AxSpA research survey.
Get your free demo today – simply fill out the form to the right.